Aptus Pharma H1 FY27 Financial Results

Revenue from operations reached Rs 48.90 crore, with Profit After Tax recorded at Rs 5.08 crore for the half-year ended September 30, 2026.

Reader Takeaway: Strong revenue growth supports strategic manufacturing expansion, though working capital management remains a primary operational monitor for investors.

What just happened

Aptus Pharma announced its financial results for the half-year ended September 30, 2026. The company reported revenue from operations of Rs 48.90 crore, a significant increase from Rs 14.38 crore in the corresponding period last year. Total profit after tax stood at Rs 5.08 crore. Additionally, management announced a strategic shift toward internal manufacturing, supported by a planned Rs 25 crore preferential issue to fund a Rs 35 crore capital expenditure project.

Strategic Roadmap

Management has committed to a three-pillar growth strategy. First, the company aims to develop internal manufacturing capabilities by March 2028, targeting 20% self-production of formulations. Second, it plans to scale distribution to achieve 46% geographic coverage across India by March 2027, with a vision for total pan-India presence by 2029. Third, it is exploring entry into Asian, African, and Latin American markets.

Risks to watch

Investors should closely track the execution of the manufacturing expansion, as it is subject to various regulatory approvals and operational requirements. Furthermore, working capital remains a focal point; trade receivables reached Rs 28.64 crore against inventory of Rs 16.25 crore as of September 30, 2026. Management has also explicitly declined to provide specific forward-looking revenue or margin guidance at this stage.

What to track next

Watch for updates on the utilization of the Rs 25 crore preferential issue funds and the progress of the manufacturing plant construction. The company's ability to maintain its revenue momentum while balancing its receivables will be critical for long-term value creation.